secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000719135-24-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical reports preliminary Q4 rev $14.2-14.6M (+13-16% YoY); FY rev $51.9-52.3M (+17-18%)
--------------------------------------------------------------------------------

- Total Q4 revenue $14.2-14.6M, growth 13-16% YoY; Advanced Energy $11.9-12.3M (+12-16%).
- Full year total revenue $51.9-52.3M (+17-18%); Advanced Energy $43.1-43.5M (+17-18%); OEM $8.8M (+14%).
- CEO says sales softer than expected due to challenging macro environment in cosmetic surgery market; slower new customer adoption.
- Company plans to release full Q4 and FY 2023 results in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/0000719135-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/apyx-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000719135-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer